Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 3/20 | 0.31 |
| ▸ | HPGDS | O60760 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31424405 | 0.88 | THRB (0.33) | THRBC5AR1TP53MAPTLMNA | |
| SCHEMBL20014821 | 0.88 | NR1H2 (0.33) | THRBC5AR1TP53MAPTLMNA | |
| SCHEMBL28952435 | 0.88 | NR1H2 (0.33) | THRBC5AR1TP53MAPTLMNA | |
| SCHEMBL31692240 | 0.87 | THRB (0.33) | THRBC5AR1TP53MAPTLMNA | |
| SCHEMBL31692242 | 0.86 | THRB (0.32) | THRBC5AR1LMNANPSR1NR1H2 | |
| SCHEMBL31692219 | 0.86 | THRB (0.34) | THRBC5AR1TP53MAPTLMNA | |
| SCHEMBL31692524 | 0.85 | THRB (0.32) | THRBC5AR1MEN1KMT2ANR1H2 | |
| SCHEMBL31692614 | 0.84 | GLP1R (0.32) | THRBLMNANPSR1NR1H2NR1H3 | |
| SCHEMBL31692363 | 0.83 | UCHL1 (0.35) | THRBGLP1R | |
| SCHEMBL31692599 | 0.83 | GLP1R (0.32) | THRBTP53LMNANPSR1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617783-B2 | Heterocyclic GLP-1R agonists | BIOMEA FUSION, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | THRB 185/4885C5AR1 1540/4885TP53 4735/4885 |
| US-12617783-B2 | Heterocyclic GLP-1R agonists | GLP1R, GIPR, GPR119 | THRB 75/4885C5AR1 626/4885TP53 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.